Voclosporin denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for voclosporin are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Quantity Limits to Voclosporin

Quantity-limit (QL) edits on specialty drugs like voclosporin are common across managed-care plans. Aetna's quantity limit is built from the FDA-approved dosing regimen described in the prescribing label. A QL denial generally arises when the quantity dispensed or requested exceeds what Aetna's system recognizes as the standard supply for the approved regimen — for example, a fill covering an unusual day-supply, a quantity written to accommodate a dose change, or a dispensing error in how the prescription was written.

Quantity-limit denials are routinely reversible when the prescribed quantity is clinically justified.

## Why This Is Appealable

The FDA-approved prescribing label defines the dosing regimen for voclosporin in lupus nephritis. If your prescriber is ordering within that label — or has a documented clinical rationale for the quantity requested — Aetna must consider that rationale. Plans cannot impose quantity limits that effectively deny medically necessary treatment.

## Your Appeal Rights

• Quantity limit exception / PA override: Your prescriber can request a QL exception through Aetna's PA process, citing the FDA label and any clinical reason the prescribed quantity is necessary (e.g., a titration schedule, a dose adjustment, or a renal-function-based adjustment per the label).
• Internal appeal (ERISA §503 / ACA): If the exception is denied, file a formal internal appeal with supporting documentation within the deadline on the denial notice.
• External review (ACA §2719): After exhausting internal appeal, request independent external review within approximately four months of the final internal denial.

## Documentation to Gather

1. FDA prescribing label — highlight the dosing and administration section, including any dose modification guidance, so the reviewer can confirm the prescribed quantity is within label. 2. Prescriber's clinical rationale — a letter explaining why the specific quantity requested is appropriate for this patient: prescribed regimen, any renal-function-based adjustment, day-supply calculation, or mid-cycle dose change. 3. Pharmacy dispensing record — confirm how the prescription was written and filled to rule out a clerical error in the quantity field. 4. Current clinical status — notes documenting disease activity and ongoing need for the medication at the prescribed level.

## Criteria-Mapping Structure

| QL Denial Basis | Rebuttal / Supporting Evidence | |---|---| | Quantity exceeds plan limit | FDA label dosing section; prescriber's quantity calculation | | Day-supply inconsistency | Pharmacy dispensing record; days-supply math | | Dose not within approved regimen | Label dose-modification table; prescriber rationale letter |

Many QL denials resolve with a corrected prescription or a brief prescriber note confirming the quantity is within the FDA label. Escalate to formal appeal only if the administrative fix fails.